New antifungal pill passes early safety check in small study
NCT ID NCT02957929
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This early-stage study tested a new oral drug called APX001 in 46 healthy adults to see if it is safe and how the body processes it. The goal was to gather information for future development of a treatment for fungal infections. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PRA Health Sciences
Groningen, Netherlands
-
PRA Health Sciences (PRA) - Early Development Services (EDS)
Groningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.